Liquidia’s stock $LQDA rose about 10% on Monday following a win in the US Supreme Court for its treprostinil inhalation ...

The news that Pfizer has an activist isn’t a surprise. For the last few months at Endpoints News, we’ve been asking which ...

Scholar Rock announced its experimental add-on treatment for spinal muscular atrophy significantly improved motor function ...

AstraZeneca is strengthening its cardiovascular disease pipeline with a $100 million upfront deal for a lipid-targeting drug ...

Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter ...

Global investment manager Oaktree is out with its third life sciences-dedicated special purpose acquisition company after ...

Upstream Bio, a mid-stage respiratory drug developer, and CAMP4 Therapeutics, a Phase 1 regulatory RNA startup, have unveiled ...

Kezar Life Sciences’ autoimmune drug candidate, zetomipzomib, has been put on hold by the FDA after the company said last ...

The activist investor Starboard Value has taken a stake in Pfizer, according to media reports, following the drugmaker's months of lackluster results as it came out of the pandemic and sought the next ...

The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to ...

The European Medicines Agency is looking more closely at medicines used to treat hair loss and a condition caused by an ...

This season’s uptake of RSV vaccines in the US has been slower than expected, according to Wall Street analysts tracking ...